Full Answer
What is the semglee® program?
It's a savings offer that may be able to reduce out-of-pocket costs on SEMGLEE ® (insulin glargine-yfgn) injection or Insulin Glargine (insulin glargine-yfgn). You may pay as little as $0 up to $94 per 30-day supply while this program remains in effect, depending upon your commercial insurance coverage.
Is semglee approved by the FDA?
Semglee is an FDA (U.S. Food and Drug Administration) approved medication manufactured by Mylan Pharmaceuticals Inc., a Viatris Company. Semglee (insulin glargine-yfgn) is an interchangeable biosimilar insulin product with its reference product Lantus (insulin glargine).
How do I contact the loyaltyscript® for the semglee savings card?
For questions regarding setup, claim transmission, patient eligibility or other issues, call the LoyaltyScript® for the SEMGLEE and Insulin Glargine (insulin glargine-yfgn) Savings Card program at 800-657-7613 (8:00 AM-8:00 PM EST, Monday-Friday).
Is semglee safe to use with other people's insulin?
For type 1 diabetes, Semglee is used together with a short-acting insulin given before meals. Do not share your syringes with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
How much insulin is in a Semglee pen?
How many vouchers per patient?
Is Semgleehcp owned by Mylan?
How do you qualify for free insulin?
Patient Assistance Program – offers free insulin to people who meet the following requirements:Be a US citizen or legal resident.Have a total household income at or below four times (400%) the federal poverty level (FPL). ... Be uninsured, or in the Medicare program.More items...•
Is Semglee discontinued?
SEMGLEE (insulin glargine-yfgn) and Insulin Glargine (insulin glargine-yfgn), co-developed by Viatris and Biocon Biologics, are now available in the U.S. market. The currently marketed non-interchangeable SEMGLEE (insulin glargine) is anticipated to be phased out by the end of the 2021 calendar year.
Is there a difference between Semglee and Semglee YFGN?
Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog. Semglee (insulin glargine-yfgn) is the first interchangeable biosimilar product approved in the U.S. for the treatment of diabetes.
Is Semglee over the counter?
SEMGLEE is a prescription long-acting man-made-insulin used to control high blood sugar in adults and children with type 1 diabetes and in adults with type 2 diabetes.
How long can Semglee be left out of fridge?
SEMGLEE STORAGE If the unopened SEMGLEE vial is stored at room temperature, up to 86°F (30°C), it should be thrown away after 28 days.
Is Semglee as good as Lantus?
Semglee contains a slightly different form of insulin glargine called insulin glargine-yfgn. But since it's a biosimilar to Lantus, there are no clinically meaningful differences between the two products. This means that Semglee is just as effective as Lantus in helping you manage your blood sugar.
Does Semglee cause weight gain?
Common side effects may include: low blood sugar; swelling, weight gain; allergic reaction, itching, rash; or.
Is there a generic for Semglee?
Semglee (insulin glargine) is the first FDA-approved interchangeable biosimilar insulin product for diabetes. Biological products, like insulin, don't have generic versions. Instead, they have biosimilars, which are insulins that are very similar to the product it's based on.
What is the newest insulin?
The U.S. Food and Drug Administration (FDA) has approved insulin lispro-aabc injection, 100 units/mL and 200 units/mL, a new rapid-acting insulin indicated to improve glycemic control in adults with type 1 and type 2 diabetes. Eli Lilly and Company is marketing the drug as Lyumjev™.
Does CVS carry Semglee?
Lantus Gets Dropped Interestingly, Semglee, which the FDA approved this summer as a biosimilar to and interchangeable to Lantus, is not on the CVS formulary list, either as a replacement or former preferred product. Semglee was originally approved under the nonbiosimilar 505(b)(2) regulatory pathway, in June 2020.
Does Semglee pen need to be refrigerated?
- Store in-use (opened) SEMGLEE vials in a refrigerator or at room temperature up to 86°F (30°C). - The SEMGLEE vials should be thrown away after 28 days, even if it still has insulin left in it. - Do not freeze SEMGLEE. - Keep SEMGLEE out of direct heat and light.
Can you substitute Semglee for Lantus?
The FDA originally approved Semglee as a biosimilar for Lantus®, a long-acting insulin injection, in June 2020. But the recent approval makes Semglee interchangeable with Lantus. This means a pharmacy can substitute Semglee for Lantus without needing to go back to the prescriber, depending on state pharmacy laws.
Can insulin glargine YFGN be substituted for Lantus?
In July 2021, FDA approved the first interchangeable biosimilar insulin product (Semglee–Viatris/Biocon Biologics, insulin glargine-yfgn), which can be substituted for its reference product (Lantus–Sanofi Aventis, insulin glargine) at the pharmacy level, depending on state pharmacy laws.
Is Semglee cheaper than Lantus?
Semglee is available by prescription in either a pen or a vial – it costs $147.98 for five 3 mL pre-filled pens or $98.65 for one 10 mL vial, which is a 65% discount from the list price of Lantus.
How much Semglee should I take?
The recommended starting dose of SEMGLEE in patients with type 2 diabetes who are not currently treated with insulin is 0.2 units/kg or up to 10 units once daily. One may need to adjust the amount and timing of short-or rapid-acting insulins and dosages of other antidiabetic drugs.
Where is Semglee manufactured?
MANUFACTURING LOCATIONS facility in Johor, Malaysia. You may label your product with the proprietary name, Semglee, and market it as 100 units/mL injection in a 3 mL single-patient-use prefilled pen and a 10 mL multiple-dose vial.
How and where should I inject insulin?
Injecting insulin is not difficult, but it does take a bit of practice. There are three main sites where insulin can be injected: the stomach area...
When is the best time to take Toujeo?
Toujeo may be given at any time of the day; however, once you have chosen a time, it is best to inject Toujeo within three hours of that time every...
How long can Toujeo stay out of the refrigerator?
Toujeo can stay out of the refrigerator for up to 56 days (8 weeks). If Toujeo if left out the refrigerator for more than 20 or 30 minutes, it shou...
Welcome SEMGLEE Saving Card
SEMGLEE ® (insulin glargine‑yfgn) injection and Insulin Glargine (insulin glargine-yfgn) injection Savings Card Terms and Conditions. With this Savings Card, you may pay as little as $0 up to $94 per 30-day supply of SEMGLEE ® (insulin glargine-yfgn) injection or Insulin Glargine (insulin glargine-yfgn) while this program remains in effect, depending upon your commercial insurance coverage.
Semglee Prices, Coupons & Savings Tips - GoodRx
Compare prices, print coupons and get savings tips for Semglee (Insulin Glargine) and other Diabetes Type 2 and Diabetes Type 1 drugs at CVS, Walgreens, and other pharmacies. Prices start at $129.81
semglee Coupons and Discount Cards - rxless
More ways to save on semglee Fill a 90-Day Supply to Save. In some cases, filling your prescription for a 90-day supply will give you a lower total cost compared to filling the same prescription multiple times for smaller amounts.
Lantus Copay Savings Card and Cost | Lantus® (insulin glargine ...
Insulins Valyou Savings Program: Sanofi insulins included in this program are: ADMELOG ® (insulin lispro injection) 100 Units/mL, TOUJEO ® SoloStar ® (insulin glargine injection) 300 Units/mL, TOUJEO ® Max SoloStar ® (insulin glargine injection) 300 Units/mL, LANTUS ® (insulin glargine injection) 100 Units/mL, INSULIN GLARGINE injection 100 Units/mL (U-100) and APIDRA ® (insulin ...
Savings Card & Patient Support | Lantus® (insulin glargine injection ...
Important Safety Information for Lantus ® (insulin glargine injection) SoloStar ®. Lantus SoloSTAR is a disposable single-patient-use prefilled insulin pen. Please talk to your healthcare provider about proper injection technique and follow instructions in the Instruction Leaflet that accompanies the pen.
Savings & Resources | BASAGLAR® (insulin glargine) injection
About 31% of new prescriptions for diabetes drugs are not filled a first time. 1 See what the BASAGLAR ® (insulin glargine) injection 100 units/mL Experience resources offer
What is semglee used for?
Semglee (insulin glargine) is a member of the insulin drug class and is commonly used for Diabetes - Type 1, and Diabetes - Type 2.
How much does a Semglee card cost?
Semglee Savings Card: Eligible commercially insured patients may pay as little as $0 per 30-day prescription with a maximum savings of $75; for more information contact the program at 800-657-7613.
Is Semglee valid with insurance?
Prices are for cash paying customers only and are not valid with insurance plans. This Semglee price guide is based on using the Drugs.com discount card which is accepted at most U.S. pharmacies.
How much insulin is in a Semglee pen?
Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day. The pre filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units. The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Semglee ® can also be given together with orally active antidiabetic medicinal products. The potency of Semglee ® is stated in units and these units are exclusive to Semglee ®. Special population: Elderly population (≤ 65 years old): progressive deterioration of renal function may lead to a steady decrease in insulin requirements. Renal impairment: insulin requirements may be diminished due to reduced insulin metabolism. Hepatic impairment: insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism. Paediatric population: For adolescents and children aged 2 years and older patients, the dose regimen (dose and timing) should be individually adjusted. For children below 2 years of age the safety and efficacy of Semglee ® have not been established. No data are available. Switch from other insulins to Semglee ® When switching from a treatment regimen with an intermediate or long acting insulin to a regimen with Semglee ®, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast acting insulin analogues or the dose of oral antidiabetic medicinal products). Switch from twice daily NPH insulin to Semglee ®: To reduce the risk of nocturnal and early morning hypoglycaemia, daily dose of once daily basal insulin should be reduced by 20-30% during the first weeks of treatment. Switch from insulin glargine 300 units/ml to Semglee ®: Semglee ® and insulin glargine 300 units/ml are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia in this group, Semglee ® dose should be reduced by approximately 20%. During the first weeks increase mealtime insulin, after this period the regimen should be adjusted individually. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. A further adjustment in dose regimen may become necessary with improved metabolic control, change of timing of insulin, patient weight or life style changes. Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Semglee ®. Method of administration Semglee ® is administered subcutaneously only. Injection sites must be rotated within a given injection area from one injection to the next. Semglee ® must not be mixed with any other insulin or diluted. Before using the pre filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). Contraindications: Known hypersensitivity to the active substances or to any of the excipients. Warnings and precautions: Warnings: Semglee ® is not the insulin of choice for the treatment of diabetic ketoacidosis. In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Changes in insulin strength, manufacturer, type, origin, method of manufacture and/or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food or are vomiting etc. and they must never omit insulin entirely. Insulin antibodies Rare chance of antibodies formation, may require insulin dose adjustment to avoid hyper- or hypoglycaemia. Handling of the pen Before using Semglee ® pen, the instructions for use included in the package leaflet must be read carefully. Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins. Interaction with other medicinal products: Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs when used with Semglee ®. Substances that may enhance the blood glucose lowering effect include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Substances that may reduce the blood glucose lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. Beta blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. Pregnancy and lactation: Pregnancy For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity. The use of Semglee ® may be considered during pregnancy, if clinically needed. The use of Semglee ® may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. Breast feeding It is unknown whether insulin glargine is excreted in human milk. Women may require adjustments in insulin dose and diet. Effects on ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. Undesirable effects: Very common: Hypoglycaemia. Common: Lipohypertrophy, Injection site reactions Uncommon: Lipoatrophy. For rare and very rare undesirable effects, please refer to SmPC. Name and Address of Marketing Authorisation Holder: Mylan S.A.S., 117 allée des Parcs, 69800 Saint Priest, France. Marketing Authorisation Number: EU/1/18/1270/003 Basic NHS price: 3ml x 5 pens=£29.99 Legal Category: POM Date of Last Revision: October 2018
What is interchangeable product?
According to the FDA, an interchangeable product is a biological product that is approved based on data demonstrating that it is highly similar to an FDA-approved reference product and that there are no clinically meaningful differences between the products. The interchangeable product can be expected to produce the same clinical result as the reference product in any given patient. Further, if the interchangeable product is administered more than once to a patient, the risk in terms of safety or diminished efficacy from alternating or switching between use of the reference product and interchangeable product is not greater than that from the reference product without such alternation or switch.
Can you use a semglee pen before or after an insulin injection?
Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.
Does Semglee cause hypoglycaemia?
Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased.
Is Semgleehcp owned by Mylan?
You are now leaving Semgleehcp.com, a Viatris website. The website you are about to access is not owned or controlled by Mylan Specialty, a Viatris Company.
Can you mix semglee with insulin?
Semglee ® must not be mixed with any other insulin or diluted. Before using the pre filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). Contraindications: Known hypersensitivity to the active substances or to any of the excipients.
Is semglee the same as lantus?
SEMGLEE – the first and only FDA-approved, long-acting insulin glargine that is interchangeable with LANTUS ® (insulin glargine) injection
What is a semglee?
SEMGLEE ® (insulin glargine injection). Instructions for use. Mylan Pharmaceuticals Inc.
Where to inject semglee?
SEMGLEE is injected under the skin (subcutaneously) of your stomach area (abdominal area), thigh, buttocks or upper arms. You should change (rotate) your injection site for each injection.
How much insulin is in a Semglee pen?
Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day. The pre filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units. The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Semglee ® can also be given together with orally active antidiabetic medicinal products. The potency of Semglee ® is stated in units and these units are exclusive to Semglee ®. Special population: Elderly population (≤ 65 years old): progressive deterioration of renal function may lead to a steady decrease in insulin requirements. Renal impairment: insulin requirements may be diminished due to reduced insulin metabolism. Hepatic impairment: insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism. Paediatric population: For adolescents and children aged 2 years and older patients, the dose regimen (dose and timing) should be individually adjusted. For children below 2 years of age the safety and efficacy of Semglee ® have not been established. No data are available. Switch from other insulins to Semglee ® When switching from a treatment regimen with an intermediate or long acting insulin to a regimen with Semglee ®, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast acting insulin analogues or the dose of oral antidiabetic medicinal products). Switch from twice daily NPH insulin to Semglee ®: To reduce the risk of nocturnal and early morning hypoglycaemia, daily dose of once daily basal insulin should be reduced by 20-30% during the first weeks of treatment. Switch from insulin glargine 300 units/ml to Semglee ®: Semglee ® and insulin glargine 300 units/ml are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia in this group, Semglee ® dose should be reduced by approximately 20%. During the first weeks increase mealtime insulin, after this period the regimen should be adjusted individually. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. A further adjustment in dose regimen may become necessary with improved metabolic control, change of timing of insulin, patient weight or life style changes. Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Semglee ®. Method of administration Semglee ® is administered subcutaneously only. Injection sites must be rotated within a given injection area from one injection to the next. Semglee ® must not be mixed with any other insulin or diluted. Before using the pre filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). Contraindications: Known hypersensitivity to the active substances or to any of the excipients. Warnings and precautions: Warnings: Semglee ® is not the insulin of choice for the treatment of diabetic ketoacidosis. In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Changes in insulin strength, manufacturer, type, origin, method of manufacture and/or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food or are vomiting etc. and they must never omit insulin entirely. Insulin antibodies Rare chance of antibodies formation, may require insulin dose adjustment to avoid hyper- or hypoglycaemia. Handling of the pen Before using Semglee ® pen, the instructions for use included in the package leaflet must be read carefully. Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins. Interaction with other medicinal products: Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs when used with Semglee ®. Substances that may enhance the blood glucose lowering effect include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Substances that may reduce the blood glucose lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. Beta blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. Pregnancy and lactation: Pregnancy For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity. The use of Semglee ® may be considered during pregnancy, if clinically needed. The use of Semglee ® may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. Breast feeding It is unknown whether insulin glargine is excreted in human milk. Women may require adjustments in insulin dose and diet. Effects on ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. Undesirable effects: Very common: Hypoglycaemia. Common: Lipohypertrophy, Injection site reactions Uncommon: Lipoatrophy. For rare and very rare undesirable effects, please refer to SmPC. Name and Address of Marketing Authorisation Holder: Mylan S.A.S., 117 allée des Parcs, 69800 Saint Priest, France. Marketing Authorisation Number: EU/1/18/1270/003 Basic NHS price: 3ml x 5 pens=£29.99 Legal Category: POM Date of Last Revision: October 2018
How many units can a semglee pen give?
The SEMGLEE pre-filled pen gives patients dosing flexibility, allowing up to 80 insulin units with a single injection.
Can you use semglee while pregnant?
The use of Semglee ® may be considered during pregnancy, if clinically needed. The use of Semglee ® may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. Breast feeding It is unknown whether insulin glargine is excreted in human milk.
How should I use Semglee?
Use Semglee exactly as prescribed by your doctor. Follow all directions on your prescription label and read all medication guides or instruction sheets.
What is semglee used for?
Semglee is used to improve blood sugar control in patients with diabetes mellitus.
What should I avoid while using Semglee?
Avoid driving or hazardous activity until you know how this medicine will affect you. Your reactions could be impaired.
What other drugs will affect Semglee?
Many drugs can affect your blood sugar and may also affect Semglee. Some medicines can increase or decrease the effects of insulin. Some drugs can also cause you to have fewer symptoms of hypoglycemia, making it harder to tell when your blood sugar is low. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Tell your doctor about all other medicines you use. Not all possible interactions are listed here.
What happens if you get allergic to semglee?
Get emergency medical help if you have any signs of an allergic reaction to Semglee: redness or swelling where an injection was given, itchy skin rash over the entire body, trouble breathing, fast heartbeats, feeling like you might pass out, or swelling in your tongue or throat.
Can you share a needle with someone else?
Do not share your syringes with other people, even if the needle has been changed. You may give other people a serious infection, or get a serious infection from them.
Is semglee good for diabetics?
Semglee is not for use to treat diabetic ketoacidosis.
What is semglee used for?from drugs.com
Semglee (insulin glargine) is a member of the insulin drug class and is commonly used for Diabetes - Type 1, and Diabetes - Type 2.
How much does a Semglee card cost?from drugs.com
Semglee Savings Card: Eligible commercially insured patients may pay as little as $0 per 30-day prescription with a maximum savings of $75; for more information contact the program at 800-657-7613.
How much insulin is in a Semglee pen?from semgleehcp.com
Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day. The pre filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units. The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Semglee ® can also be given together with orally active antidiabetic medicinal products. The potency of Semglee ® is stated in units and these units are exclusive to Semglee ®. Special population: Elderly population (≤ 65 years old): progressive deterioration of renal function may lead to a steady decrease in insulin requirements. Renal impairment: insulin requirements may be diminished due to reduced insulin metabolism. Hepatic impairment: insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism. Paediatric population: For adolescents and children aged 2 years and older patients, the dose regimen (dose and timing) should be individually adjusted. For children below 2 years of age the safety and efficacy of Semglee ® have not been established. No data are available. Switch from other insulins to Semglee ® When switching from a treatment regimen with an intermediate or long acting insulin to a regimen with Semglee ®, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast acting insulin analogues or the dose of oral antidiabetic medicinal products). Switch from twice daily NPH insulin to Semglee ®: To reduce the risk of nocturnal and early morning hypoglycaemia, daily dose of once daily basal insulin should be reduced by 20-30% during the first weeks of treatment. Switch from insulin glargine 300 units/ml to Semglee ®: Semglee ® and insulin glargine 300 units/ml are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia in this group, Semglee ® dose should be reduced by approximately 20%. During the first weeks increase mealtime insulin, after this period the regimen should be adjusted individually. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. A further adjustment in dose regimen may become necessary with improved metabolic control, change of timing of insulin, patient weight or life style changes. Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Semglee ®. Method of administration Semglee ® is administered subcutaneously only. Injection sites must be rotated within a given injection area from one injection to the next. Semglee ® must not be mixed with any other insulin or diluted. Before using the pre filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). Contraindications: Known hypersensitivity to the active substances or to any of the excipients. Warnings and precautions: Warnings: Semglee ® is not the insulin of choice for the treatment of diabetic ketoacidosis. In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Changes in insulin strength, manufacturer, type, origin, method of manufacture and/or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food or are vomiting etc. and they must never omit insulin entirely. Insulin antibodies Rare chance of antibodies formation, may require insulin dose adjustment to avoid hyper- or hypoglycaemia. Handling of the pen Before using Semglee ® pen, the instructions for use included in the package leaflet must be read carefully. Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins. Interaction with other medicinal products: Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs when used with Semglee ®. Substances that may enhance the blood glucose lowering effect include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Substances that may reduce the blood glucose lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. Beta blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. Pregnancy and lactation: Pregnancy For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity. The use of Semglee ® may be considered during pregnancy, if clinically needed. The use of Semglee ® may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. Breast feeding It is unknown whether insulin glargine is excreted in human milk. Women may require adjustments in insulin dose and diet. Effects on ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. Undesirable effects: Very common: Hypoglycaemia. Common: Lipohypertrophy, Injection site reactions Uncommon: Lipoatrophy. For rare and very rare undesirable effects, please refer to SmPC. Name and Address of Marketing Authorisation Holder: Mylan S.A.S., 117 allée des Parcs, 69800 Saint Priest, France. Marketing Authorisation Number: EU/1/18/1270/003 Basic NHS price: 3ml x 5 pens=£29.99 Legal Category: POM Date of Last Revision: October 2018
What is interchangeable biologic?from semgleehcp.com
An interchangeable biologic product is a biosimilar that meets additional requirements and may be substituted for the reference product at the pharmacy, depending on state pharmacy laws.
Can you use a semglee pen before or after an insulin injection?from semgleehcp.com
Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.
Does Semglee cause hypoglycaemia?from semgleehcp.com
Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased.
Is Semgleehcp owned by Viatris?from semgleehcp.com
You are now leaving Semgleehcp.com, a Viatris website. The website you are about to access is not owned or controlled by Mylan Specialty, a Viatris Company. Mylan Specialty assumes no responsibility for, and makes no representation as to the accuracy of, any content contained on the website you are about to access.
What is semglee used for?from drugs.com
Semglee (insulin glargine) is a member of the insulin drug class and is commonly used for Diabetes - Type 1, and Diabetes - Type 2.
How much does a Semglee card cost?from drugs.com
Semglee Savings Card: Eligible commercially insured patients may pay as little as $0 per 30-day prescription with a maximum savings of $75; for more information contact the program at 800-657-7613.
How much insulin is in a Semglee pen?from semgleehcp.com
Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day. The pre filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units. The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Semglee ® can also be given together with orally active antidiabetic medicinal products. The potency of Semglee ® is stated in units and these units are exclusive to Semglee ®. Special population: Elderly population (≤ 65 years old): progressive deterioration of renal function may lead to a steady decrease in insulin requirements. Renal impairment: insulin requirements may be diminished due to reduced insulin metabolism. Hepatic impairment: insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism. Paediatric population: For adolescents and children aged 2 years and older patients, the dose regimen (dose and timing) should be individually adjusted. For children below 2 years of age the safety and efficacy of Semglee ® have not been established. No data are available. Switch from other insulins to Semglee ® When switching from a treatment regimen with an intermediate or long acting insulin to a regimen with Semglee ®, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast acting insulin analogues or the dose of oral antidiabetic medicinal products). Switch from twice daily NPH insulin to Semglee ®: To reduce the risk of nocturnal and early morning hypoglycaemia, daily dose of once daily basal insulin should be reduced by 20-30% during the first weeks of treatment. Switch from insulin glargine 300 units/ml to Semglee ®: Semglee ® and insulin glargine 300 units/ml are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia in this group, Semglee ® dose should be reduced by approximately 20%. During the first weeks increase mealtime insulin, after this period the regimen should be adjusted individually. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. A further adjustment in dose regimen may become necessary with improved metabolic control, change of timing of insulin, patient weight or life style changes. Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Semglee ®. Method of administration Semglee ® is administered subcutaneously only. Injection sites must be rotated within a given injection area from one injection to the next. Semglee ® must not be mixed with any other insulin or diluted. Before using the pre filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). Contraindications: Known hypersensitivity to the active substances or to any of the excipients. Warnings and precautions: Warnings: Semglee ® is not the insulin of choice for the treatment of diabetic ketoacidosis. In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Changes in insulin strength, manufacturer, type, origin, method of manufacture and/or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food or are vomiting etc. and they must never omit insulin entirely. Insulin antibodies Rare chance of antibodies formation, may require insulin dose adjustment to avoid hyper- or hypoglycaemia. Handling of the pen Before using Semglee ® pen, the instructions for use included in the package leaflet must be read carefully. Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins. Interaction with other medicinal products: Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs when used with Semglee ®. Substances that may enhance the blood glucose lowering effect include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Substances that may reduce the blood glucose lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. Beta blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. Pregnancy and lactation: Pregnancy For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity. The use of Semglee ® may be considered during pregnancy, if clinically needed. The use of Semglee ® may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. Breast feeding It is unknown whether insulin glargine is excreted in human milk. Women may require adjustments in insulin dose and diet. Effects on ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. Undesirable effects: Very common: Hypoglycaemia. Common: Lipohypertrophy, Injection site reactions Uncommon: Lipoatrophy. For rare and very rare undesirable effects, please refer to SmPC. Name and Address of Marketing Authorisation Holder: Mylan S.A.S., 117 allée des Parcs, 69800 Saint Priest, France. Marketing Authorisation Number: EU/1/18/1270/003 Basic NHS price: 3ml x 5 pens=£29.99 Legal Category: POM Date of Last Revision: October 2018
What is interchangeable biologic?from semgleehcp.com
An interchangeable biologic product is a biosimilar that meets additional requirements and may be substituted for the reference product at the pharmacy, depending on state pharmacy laws.
Can you use a semglee pen before or after an insulin injection?from semgleehcp.com
Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins.
Does Semglee cause hypoglycaemia?from semgleehcp.com
Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased.
Is Semgleehcp owned by Viatris?from semgleehcp.com
You are now leaving Semgleehcp.com, a Viatris website. The website you are about to access is not owned or controlled by Mylan Specialty, a Viatris Company. Mylan Specialty assumes no responsibility for, and makes no representation as to the accuracy of, any content contained on the website you are about to access.
How much insulin is in a Semglee pen?
Presentation: Each ml contains 100 units insulin glargine* (equivalent to 3.64 mg). Each pen contains 3 ml of solution for injection, equivalent to 300 units. Dosage and administration: Semglee ® (insulin glargine) has a prolonged duration of action. It should be administered once daily at any time but at the same time each day. The pre filled pen delivers insulin in increments of 1 unit up to a maximum single dose of 80 units. The dose regimen (dose and timing) should be individually adjusted. In patients with type 2 diabetes mellitus, Semglee ® can also be given together with orally active antidiabetic medicinal products. The potency of Semglee ® is stated in units and these units are exclusive to Semglee ®. Special population: Elderly population (≤ 65 years old): progressive deterioration of renal function may lead to a steady decrease in insulin requirements. Renal impairment: insulin requirements may be diminished due to reduced insulin metabolism. Hepatic impairment: insulin requirements may be diminished due to reduced capacity for gluconeogenesis and reduced insulin metabolism. Paediatric population: For adolescents and children aged 2 years and older patients, the dose regimen (dose and timing) should be individually adjusted. For children below 2 years of age the safety and efficacy of Semglee ® have not been established. No data are available. Switch from other insulins to Semglee ® When switching from a treatment regimen with an intermediate or long acting insulin to a regimen with Semglee ®, a change of the dose of the basal insulin may be required and the concomitant antidiabetic treatment may need to be adjusted (dose and timing of additional regular insulins or fast acting insulin analogues or the dose of oral antidiabetic medicinal products). Switch from twice daily NPH insulin to Semglee ®: To reduce the risk of nocturnal and early morning hypoglycaemia, daily dose of once daily basal insulin should be reduced by 20-30% during the first weeks of treatment. Switch from insulin glargine 300 units/ml to Semglee ®: Semglee ® and insulin glargine 300 units/ml are not bioequivalent and are not directly interchangeable. To reduce the risk of hypoglycemia in this group, Semglee ® dose should be reduced by approximately 20%. During the first weeks increase mealtime insulin, after this period the regimen should be adjusted individually. Close metabolic monitoring is recommended during the switch and in the initial weeks thereafter. A further adjustment in dose regimen may become necessary with improved metabolic control, change of timing of insulin, patient weight or life style changes. Patients with high insulin doses because of antibodies to human insulin may experience an improved insulin response with Semglee ®. Method of administration Semglee ® is administered subcutaneously only. Injection sites must be rotated within a given injection area from one injection to the next. Semglee ® must not be mixed with any other insulin or diluted. Before using the pre filled pen, the instructions for use included in the package leaflet must be read carefully (see section 6.6). Contraindications: Known hypersensitivity to the active substances or to any of the excipients. Warnings and precautions: Warnings: Semglee ® is not the insulin of choice for the treatment of diabetic ketoacidosis. In case of insufficient glucose control or a tendency to hyper- or hypoglycaemic episodes, the patient's adherence to the prescribed treatment regimen, injection sites and proper injection technique and all other relevant factors must be reviewed before dose adjustment is considered. Changes in insulin strength, manufacturer, type, origin, method of manufacture and/or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Hypoglycaemia Due to more sustained basal insulin supply with Semglee ®, less nocturnal but more early morning hypoglycaemia can be expected. Intercurrent illness In many cases urine tests for ketones are indicated, and often it is necessary to adjust the insulin dose. The insulin requirement is often increased. Patients with type 1 diabetes must continue to consume at least a small amount of carbohydrates on a regular basis, even if they are able to eat only little or no food or are vomiting etc. and they must never omit insulin entirely. Insulin antibodies Rare chance of antibodies formation, may require insulin dose adjustment to avoid hyper- or hypoglycaemia. Handling of the pen Before using Semglee ® pen, the instructions for use included in the package leaflet must be read carefully. Semglee ® pen has to be used as recommended in the instructions for use. Medication errors Insulin label must always be checked before each injection to avoid medication errors between insulin glargine and other insulins. Interaction with other medicinal products: Pioglitazone should be discontinued if any deterioration in cardiac symptoms occurs when used with Semglee ®. Substances that may enhance the blood glucose lowering effect include oral antidiabetic medicinal products, angiotensin converting enzyme (ACE) inhibitors, disopyramide, fibrates, fluoxetine, monoamine oxidase (MAO) inhibitors, pentoxifylline, propoxyphene, salicylates and sulfonamide antibiotics. Substances that may reduce the blood glucose lowering effect include corticosteroids, danazol, diazoxide, diuretics, glucagon, isoniazid, oestrogens and progestogens, phenothiazine derivatives, somatropin, sympathomimetic medicinal products (e.g. epinephrine [adrenaline], salbutamol, terbutaline), thyroid hormones, atypical antipsychotic medicinal products (e.g. clozapine and olanzapine) and protease inhibitors. Beta blockers, clonidine, lithium salts or alcohol may either potentiate or weaken the blood glucose lowering effect of insulin. Pentamidine may cause hypoglycaemia, which may sometimes be followed by hyperglycaemia. Pregnancy and lactation: Pregnancy For insulin glargine no clinical data on exposed pregnancies from controlled clinical studies are available. A large amount of data on pregnant women (more than 1000 pregnancy outcomes) indicate no specific adverse effects of insulin glargine on pregnancy and no specific malformative nor feto/neonatal toxicity of insulin glargine. Animal data do not indicate reproductive toxicity. The use of Semglee ® may be considered during pregnancy, if clinically needed. The use of Semglee ® may be considered during pregnancy, if clinically needed. Careful monitoring of glucose control is essential. Breast feeding It is unknown whether insulin glargine is excreted in human milk. Women may require adjustments in insulin dose and diet. Effects on ability to drive and use machines: The patient's ability to concentrate and react may be impaired as a result of hypoglycaemia or hyperglycaemia or, for example, as a result of visual impairment. Undesirable effects: Very common: Hypoglycaemia. Common: Lipohypertrophy, Injection site reactions Uncommon: Lipoatrophy. For rare and very rare undesirable effects, please refer to SmPC. Name and Address of Marketing Authorisation Holder: Mylan S.A.S., 117 allée des Parcs, 69800 Saint Priest, France. Marketing Authorisation Number: EU/1/18/1270/003 Basic NHS price: 3ml x 5 pens=£29.99 Legal Category: POM Date of Last Revision: October 2018
How many vouchers per patient?
A valid prescription must accompany the voucher. One voucher redemption per patient.
Is Semgleehcp owned by Mylan?
You are now leaving Semgleehcp.com, a Viatris website. The website you are about to access is not owned or controlled by Mylan Specialty, a Viatris Company.